| Literature DB >> 23914236 |
F Arabkhazaeli1, M Modrisanei, S Nabian, B Mansoori, A Madani.
Abstract
BACKGROUND: In this study, the presence of resistance to diclazuril, amprolium+ethopabate and salinomycin, representing some of the commonest anticoccidials in Iran's poultry industry, against three mixed Eimeria field isolates were investigated.Entities:
Keywords: Anticoccidial Sensitivity Test; Drug resistance; Eimeria; Global Index; Optimum Anticoccidial Activity
Year: 2013 PMID: 23914236 PMCID: PMC3724148
Source DB: PubMed Journal: Iran J Parasitol ISSN: 1735-7020 Impact factor: 1.012
Anticoccidials and infective dose inoculated to each of the treatment groups
| Treatment | Isolate* | Inoculated infective dose | Anticoccidials |
|---|---|---|---|
| 1 | 1 | 300000 oocyst/bird | Salinomycin @ 500 ppm |
| 2 | 2 | 300000 oocyst/bird | Salinomycin @ 500 ppm |
| 3 | 3 | 250000 oocyst/bird | Salinomycin @ 500 ppm |
| 4 | 1 | 300000 oocyst/bird | Amprolium+Ethopabate @ 500 ppm |
| 5 | 2 | 300000 oocyst/bird | Amprolium+Ethopabate @ 500 ppm |
| 6 | 3 | 250000 oocyst/bird | Amprolium+Ethopabate @ 500 ppm |
| 7 | 1 | 300000 oocyst/bird | Diclazuril @ 200 ppm |
| 8 | 2 | 300000 oocyst/bird | Diclazuril @ 200 ppm |
| 9 | 3 | 250000 oocyst/bird | Diclazuril @ 200 ppm |
| 10 | 1 | 300000 oocyst/bird | Non-medicated |
| 11 | 2 | 300000 oocyst/bird | Non-medicated |
| 12 | 3 | 250000 oocyst/bird | Non-medicated |
| 13 | Non-Infected | - | Non-medicated |
| 14 | Non-Infected | - | Salinomycin |
| 15 | Non-Infected | - | Amprolium+Ethopabate |
| 16 | Non-Infected | - | Diclazuril |
Evaluation of developing resistance in three chicken Eimeria field isolates in coccidian-infected broiler chicks
| Experimental group | AWG (g) | FCR (g/g) | Lesion score | Oocyst index | %GINNC | %OAA | AST | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ea | Em | Emi | Et | ||||||||
|
| Salinomycin | 307.4 | 1.7 | 0.7 | 1.3 | LE | PR | S | PR | S | S |
| Amprolium+ethopabate | 252.7 | 2.01 | 0.9 | 1.5 | PR | R | PR | S | R | S | |
| Diclazuril | 254.5 | 1.9 | 0.9 | 1.6 | PR | R | PR | PR | S | S | |
| INC | 237.1 | 2.03 | 1.9 | 1.4 | |||||||
| NNC | 348.5 | 1.6 | - | - | |||||||
| S.E.M. | 12.0 | 0.04 | 0.14 | 0.14 | |||||||
|
| Salinomycin | 284.9 | 1.77 | 0.8 | 1.0 | LE | PR | R | R | R | S |
| Amprolium+ethopabate | 213.7 | 2.1 | 0.9 | 1.6 | R | R | R | R | PR | S | |
| Diclazuril | 224.3 | 1.9 | 1.0 | 1.1 | PR | R | R | R | R | S | |
| INC | 205.6 | 2.03 | 1.5 | 0.8 | |||||||
| NNC | 348.5 | 1.65 | - | - | |||||||
| S.E.M. | 14.9 | 0.04 | 0.09 | 0.13 | |||||||
|
| Salinomycin | 249.6 | 1.74 | 1.5 | 1.5 | PR | PR | R | PR | PR | PR |
| Amprolium+ethopabate | 196.9 | 2.1 | 2.1 | 1.2 | R | R | R | PR | R | R | |
| Diclazuril | 258.1 | 1.7 | 1.2 | 1.9 | PR | PR | R | PR | R | S | |
| INC | 145.3d | 2.75 | 2.3 | 2.6 | |||||||
| NNC | 348.5 | 1.65 | - | - | |||||||
| S.E.M. | 18.6 | 0.12 | 0.17 | 0.23 | |||||||
Means sharing the same superscripts within each section do not differ (P ≤ 0.05).
AWG: Average weight gain: FCR: Feed conversion ratio; INC: Infected Non-medicated Control group; NNC: Non- Infected Non- medicated Control group;%GINNC=%WGNNC-[(FM-FNNC)×10]-(OIM-OIINC)-[(LSM-LSINC)×2)]-(%mortality/2) where GI is Global Index, WG is weight gain, F is FCR, OI is oocyst index, LS is lesion score, M is medicated group;%OAA=[average GSR of medicated group-average GSR of INC]/average GSR of NNC-average GSR of INC]×100 where OAA is Optimum Anticoccidial Activity, GSR is Growth and Survival Ratio calculated as the cage weight at trial termination+the weight of any dead bird/the cage weight when infected; AST= 100%-(mean lesion score of medicated group-mean lesion score of INC×100%) wher AST is Anticoccidial Sensitivity Test; Ea: Eimeria acervulina; Em: E. maxima; Emi: E. mitis; Et: E. tenella; LE: Limited Efficacy; PR: Partially Resistant; RS: Reduced Sensitivity; R: Resistant; S: Sensitive;